Publications scientifiques
Lazare Sidjui Sidjui
Autres affiliations : Institut de Recherches Médicales et d’Etudes des Plantes Médicinales
Yves Nganso Ditchou
Autres affiliations : University of Maroua
Désiré Soh
Autres affiliations : University of Bamenda
Raoul Kemzeu
Fabrice Fekam Boyom
Gabrielle Amang à Ngnoung
Autres affiliations : Institut de Recherches Médicales et d’Etudes des Plantes Médicinales
Peron Bosco Leutcha
Alain Méli Lannang
Autres affiliations : University of Ngaoundéré
Lauve Rachel Yamthe Tchokouaha
Théodora Kopa Kowa
Alembert Tiabou Tchinda
Gaëtan Herbette
Autres affiliations : Centrale Marseille
Béatrice Baghdikian
Autres affiliations : Université d'Avignon et des Pays de Vaucluse · Institut de Recherche pour le Développement
Madan Poka
Patrick H. Demana
Xavier Siwe‐Noundou* (Auteur correspondant)
Molecules
Antrocaryon klaineanum is traditionally used for the treatment of back pain, malaria, female sterility, chlamydiae infections, liver diseases, wounds, and hemorrhoid. This work aimed at investigating the bioactive compounds with antileishmanial and antiplasmodial activities from A. klaineanum. An unreported glucocerebroside antroklaicerebroside (1) together with five known compounds (2–6) were isolated from the root barks of Antrocaryon klaineanum using chromatographic techniques. The NMR, MS, and IR spectroscopic data in association with previous literature were used for the characterization of all the isolated compounds. Compounds 1–4 are reported for the first time from A. klaineanum. The methanol crude extract (AK-MeOH), the n-hexane fraction (AK-Hex), the dichloromethane fraction (AK-DCM), the ethyl acetate fraction (AK-EtOAc), and compounds 1–6 were all evaluated for their antiparasitic effects against Plasmodium falciparum strains susceptible to chloroquine (3D7), resistant to chloroquine (Dd2), and promastigotes of Leishmania donovani (MHOM/SD/62/1S). The AK-Hex, AK-EtOAc, AK-MeOH, and compound 2 were strongly active against Dd2 strain with IC50 ranging from 2.78 ± 0.06 to 9.30 ± 0.29 µg/mL. Particularly, AK-MeOH was the most active—more than the reference drugs used—with an IC50 of 2.78 ± 0.06 µg/mL. The AK-EtOAc as well as all the tested compounds showed strong antileishmanial activities with IC50 ranging from 4.80 ± 0.13 to 9.14 ± 0.96 µg/mL.
